Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Cash from Operations: 2016-2025

Historic Cash from Operations for UroGen Pharma (URGN) over the last 8 years, with Sep 2025 value amounting to -$42.3 million.

  • UroGen Pharma's Cash from Operations fell 52.80% to -$42.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$137.7 million, marking a year-over-year decrease of 43.26%. This contributed to the annual value of -$96.8 million for FY2024, which is 26.70% down from last year.
  • UroGen Pharma's Cash from Operations amounted to -$42.3 million in Q3 2025, which was down 6.14% from -$39.8 million recorded in Q2 2025.
  • Over the past 5 years, UroGen Pharma's Cash from Operations peaked at -$13.0 million during Q4 2023, and registered a low of -$42.3 million during Q3 2025.
  • For the 3-year period, UroGen Pharma's Cash from Operations averaged around -$27.0 million, with its median value being -$25.8 million (2023).
  • As far as peak fluctuations go, UroGen Pharma's Cash from Operations spiked by 40.25% in 2023, and later tumbled by 67.70% in 2025.
  • Over the past 5 years, UroGen Pharma's Cash from Operations (Quarterly) stood at -$20.1 million in 2021, then dropped by 8.38% to -$21.8 million in 2022, then spiked by 40.25% to -$13.0 million in 2023, then decreased by 4.79% to -$13.6 million in 2024, then tumbled by 52.80% to -$42.3 million in 2025.
  • Its last three reported values are -$42.3 million in Q3 2025, -$39.8 million for Q2 2025, and -$42.0 million during Q1 2025.